HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellness New Product Roundup: 'The Truth' CBD, Hilo Performance Gummies, Syntech Offers More In US

Executive Summary

Wakunaga expands Kyo-Dophilus probiotic line; Avadim Health's Theraworx reaches pharmacies; Naturade expands VeganSmart line; Goodbye UTI supplement contains d-mannose; Hilo Nutrition workout gummies alternative to powders, liquids; Syntech Nutrition adds to US distribution; and former NBA great Paul Pierce enters wellness business with cannabidiol oils, vaporizers.

You may also be interested in...

FDA Decision On CBD Use Could Run Up Against Chicken Or Egg Question

Speakers at FDA's first-ever public hearing on using cannabis-derived ingredients in products subject to its oversight asked agency officials to look back further than history of drug research with cannabinoids to earlier than the origin of its regulations as it considers its decision. "CBD is a constituent inherent in hemp which has been marketed and used at least since the Civil War," says cannabis business attorney Rob Kight.

Health, Beauty And Wellness News: Nutrisystem Adds Options, Roar Gains $5.6M, SynTech Elite In US, More News

Nurtisystem launches FreshStart, South Beach Keto; Roar Beverage $5.6m funding led by AccelFoods; SynTech brings Elite Series to US; ChromaDex extends Tru Niagen to Canada with Fullscript; Nugenix Sexual Vitality Booster with Nitrosigine; Abattis debuts Vergence Naturals with Comfort; Brueggman takes Vitaquest helm; and CBD Bath Soaks from allitom.

COVID-19 Vaccine Skycovion Among Raft Of New EU Filings

EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts